Table 1.
Ref | Author | Selection | Comparability | Outcomes | Quality score |
---|---|---|---|---|---|
[17] | Asahi Y | ★★★★ | ★ | ★ | 6/9 |
[18] | Goeppert B | ★★★★ | ★ | ★★ | 7/9 |
[19] | Hasita H | ★★★★ | ★★ | ★★ | 8/9 |
[20] | Kim HD | ★★★ | ★★ | ★ | 6/9 |
[21] | Kim R | ★★★ | ★★ | ★★ | 7/9 |
[22] | Kitano Y | ★★★★ | ★★ | ★★ | 8/9 |
[23] | Lu JC | ★★★★ | ★★ | ★ | 7/9 |
[24] | Miura T | ★★★★ | ★★ | ★★ | 9/9 |
[25] | Oshikiri T | ★★★★ | ★★ | ★ | 7/9 |
[26] | Tian L | ★★★★ | ★★ | ★★★ | 9/9 |
[27] | Ueno T | ★★★★ | ★★ | ★★★ | 9/9 |
[28] | Vigano L | ★★★ | ★★ | ★★ | 7/9 |
[29] | Wu H | ★★★★ | ★★ | ★★ | 8/9 |
[30] | Xu YP | ★★★★ | ★★ | ★★ | 8/9 |
All included translational studies reporting oncological outcome were evaluated in accordance with the Newcastle-Ottawa scale [16]. The maximum score of the scale is nine points with studies being categorized as low (0-3 points), moderate (4-6 points) and high quality (7-9 points), respectively